IPSEN news, videos and press releases - Page 6
For more news please use our advanced search feature.
IPSEN - More news...
IPSEN - More news...
- Half-year Statement of IPSEN Liquidity Agreement With NATIXIS ODDO BHF
- IPSEN: Disclosure Transaction in Own Shares Between 28/06/2021 and 02/07/2021
- Ipsen: Disclosure Transaction in Own Shares Between 21/06/2021 and 25/06/2021
- Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer
- Ipsen: Disclosure Transaction in Own Shares Between 14/06/2021 and 18/06/2021
- Ipsen: Disclosure Transaction in Own Shares between 07/06/2021 and 11/06/2021
- ISPRM 2021: New Ipsen Analysis Highlights Potential Treatment Gap in Adults Living With Spasticity
- Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital
- Ipsen: Disclosure Transaction in Own Shares between 31/05/2021 and 04/06/2021
- Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021
- Ipsen Initiates a Share Buy-back Program to Cover Its Performance and Employee Share Plans
- Ipsen Announces the Launch of an Employee Shareholding Plan
- Ipsen Confirms U.S. FDA Accepts New Drug Application for Palovarotene as the First Potential Treatment Worldwide for Fibrodysplasia Ossificans Progressiva (FOP)
- Combined Shareholders’ Meeting of Ipsen S.A. Held on 27 May 2021
- Ipsen: Description of the Regulatory Framework of the Share Repurchase Program Proposed by the Board of Directors to Be Approved at the Combined Shareholders’ Meeting on 27 May 2021 (17th resolution)
- Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital
- Ipsen Opts-in to Join Exelixis With Ongoing Development of Cabometyx® for People Living With a Form of Thyroid Cancer, Based on Promising Interim Results
- Ipsen: Information Relating to the Combined Shareholders’ Meeting of 27 May 2021
- Ipsen Delivers Encouraging Sales Growth in the First Quarter of 2021 Despite the Pandemic, and Confirms Its Full-Year Guidance
- Ipsen Publishes its 2020 Universal Registration Document
- Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital
- European Commission Approves Cabometyx® in Combination With Opdivo® as a First-Line Treatment for Patients Living With Advanced Renal Cell Carcinoma
- Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital
- Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination With Opdivo® as First-line Treatment for Patients Living With Advanced Renal Cell Carcinoma
- Ipsen Announces New Data from the Phase II CLARINET FORTE Study Which Demonstrated Preservation of Quality of Life When Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide)
- Ipsen: Monthly Information Relative to the Total Number of Voting Rights and Shares Composing the Share Capital
- Ipsen Delivered Sales Growth and Margin Expansion in 2020 - Focused on Executing New Strategy and Delivering Financial Objectives in 2021
- Ipsen: New Data From Pivotal Phase III CheckMate -9ER trial of Cabometyx® in Combination with Opdivo® Showed Significantly Improved QoL Benefits and Sustained Superior Efficacy Versus sunitinib in Patients Living with aRCC
- Ipsen to Showcase Commitment to Going Beyond Traditional Outcome Measures for Patients Living With Renal Cell Carcinoma at ASCO GU 2021
- Ipsen Appoints Gwenan White as Executive Vice President, Communications and Public Affairs
